Welcome to our dedicated page for Calidi Biotherapeutics SEC filings (Ticker: CLDI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Calidi Biotherapeutics, Inc. (CLDI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Calidi is a clinical-stage immuno-oncology company listed on the NYSE American, and its filings offer detailed information on financial results, capital raises, material agreements, and progress in developing its RedTail oncolytic virus platform and lead candidate CLD-401.
Through current reports on Form 8-K, Calidi reports material events such as underwritten public offerings, changes in executive roles, establishment of a Scientific Advisory Board, and key development milestones, including preclinical data presentations for CLD-401 and updates on IND-enabling activities. These filings also reference press releases that describe how the RedTail platform is designed for systemic delivery, immune evasion, targeting of metastatic sites, and expression of genetic medicines like IL-15 superagonist in the tumor microenvironment.
Registration statements such as Form S-1 and periodic reports on Forms 10-K and 10-Q (when available) provide additional context on Calidi’s risk factors, financial condition, capital structure, and use of proceeds from securities offerings. Together, these documents help investors understand how the company funds its research and development in biotechnology and immuno-oncology.
On Stock Titan, CLDI filings are supplemented with AI-powered summaries that highlight key terms, financial metrics, and development updates from lengthy documents. Users can quickly scan new 8-Ks, 10-Qs, 10-Ks, and related exhibits, while also reviewing details on equity offerings, warrant terms, and other securities disclosures referenced in Calidi’s filings.